Axonics, Inc.

NasdaqGS:AXNX Lagerbericht

Marktkapitalisierung: US$3.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Axonics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Gewinne von Axonics sind jährlich um durchschnittlich 28.1% gestiegen, während die Gewinne der Branche Medical Equipment jährlich um gewachsen um 13.6% gestiegen sind. Die Umsätze sind jährlich um gewachsen 41.3% gestiegen.

Wichtige Informationen

28.06%

Wachstumsrate der Gewinne

37.96%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie8.90%
Wachstumsrate der Einnahmen41.31%
Eigenkapitalrendite-0.85%
Netto-Marge-1.31%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Seeking Alpha • Nov 05

Axonics' Market Growth Strengthens Boston Scientific's Future

Summary Boston Scientific Corporation plans to acquire Axonics, Inc. for $3.7 billion in cash to expand its urology offerings with Axonics' innovative urinary and bowel disorder treatments. Axonics, founded in 2013, is renowned for developing less invasive treatments for bladder and bowel issues, including a neurostimulator with a 20-year battery life. Boston Scientific, a major player in medical technology since 1979, will enhance its sacral neuromodulation capabilities through this acquisition. The acquisition positions Boston Scientific to better support individuals with chronic bladder and bowel conditions, strengthening its market presence in this growing field. Read the full article on Seeking Alpha
Analyseartikel • Jul 14

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Key Insights Axonics' estimated fair value is US$55.68 based on 2 Stage Free Cash Flow to Equity Current share price of...
Analyseartikel • Jun 20

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Axonics, Inc.'s ( NASDAQ:AXNX ) price-to-sales (or "P/S") ratio of 8.8x might make it look like a strong sell right now...
Analyseartikel • Mar 27

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Axonics fair value estimate is US$70.50 Current share price of...
Analyseartikel • Feb 28

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Nov 28

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Does the November share price for Axonics, Inc. ( NASDAQ:AXNX ) reflect what it's really worth? Today, we will estimate...
Seeking Alpha • Oct 10

Axonics stock falls 5.6% after Needham downgrades rating

Axonics (NASDAQ:AXNX) is trading 5.6% lower after Needham downgraded rating to hold from buy. The analyst Mike Matson sees a less favorable risk/reward profile after Needham's urologist survey suggested the company may have difficulty driving upside to consensus 2023 revenue estimates. Matson says Axonics F15 product cycle is now largely reflected in the shares, and no additional major product cycles are expected in the next 12-18 months. He believes the stock now appears to be fairly valued. AXNX is up 7.5% in the last 12 months.
Seeking Alpha • Sep 07

Axonics Stock Is A Buy Amid Current Capex Cycle

Summary Axonics looks well-positioned to continue its recent upside on the chart, with a number of idiosyncratic tailwinds yet to be recognized. The recent equity underwriting of $35mm is noted, although this is hardly a risk given intended use for capital initiatives. Shares are trading at a premium relative to peers within the sector, however, valuations are more appealing on a composite of measures. On the culmination of these factors, we rate AXNX a buy. Investment summary Considering the systematic drivers of equity returns are well at play (namely, macroeconomic drivers, rates, industry factors, and growth factors) in markets right now, we argue to seek out exposure to idiosyncratic risk premia in order to derive risk-adjusted alpha. With this front of mind, we rate Axonics, Inc. (AXNX) a speculative buy following Q2 results and additional market factors discussed below. The company's niche operating segment continues to offer a defensible growth play albeit with little correlation to equity markets, attractive features in the current investment landscape. In addition to these points, shares are trading at multiples above the peer median; however, this is balanced when factoring in a number of inputs into the valuation debate. With this, and recent momentum on the chart in mind, we rate AXNX a buy. Exhibit 1. AXNX 6-month price action Data: Refinitiv Eikon How current market factors impact AXNX The high-beta trade has unwound itself in FY22, and investors must now find selective opportunities with asymmetrical pricing within risk assets. Factor rotations have also been of high magnitude this year as well. Continuing its return to grace, value caught a strong bid from the June bounce, as seen in Exhibit 2. Investors have nibbled at compressed multiples in June-August as yields stabilized and a slight tightening of inflation. Value also continues to attract strategic positioning as managers seek to wind back equity duration and beta. Meanwhile, growth as caught a bid since this time as well, particularly in late August. This has direct implications to the outlook of the AXNX share price. With cash flows priced out into the future, we need investors to be net buyers of growth - and pay a premium at that to capture market-derived alpha when looking ahead. Exhibit 2. Both growth and value have caught a bid since the June bounce, highlighting some return in confidence to equities Data: Updata Meanwhile, whist yields have rolled over in recent months, alongside stock/bond correlations, a recent spike in the VIX and the long-end suggests stocks may not be out of the water, and raises questions on the validity of the relief rally outlined above. Exhibit 3. Whilst stock/bond correlations and yields have rolled over in recent months, recent spikes in volatility in stocks and steepness at the long-end suggest we aren't out of the woods at all Data: Updata Q2 earnings conducive of growth play AXNX generated total revenue of $69 million ("mm") last quarter, a 50% YoY growth schedule. Upside was driven by sacral neuromodulation ("SNM") revenue of $55.8mm, a 39% YoY gain. Nearly 100% of turnover was generated in the US, mitigating FOREX headwinds (although, the company did recognize a $12mm non-cash forex adjustment in its comprehensive loss). Q2 SNM sales were propped by the launch of the recharge-free Axonics F15 system. Meanwhile, Bulkamid sales came in at ~$13mm with ~$3mm in ex-US revenue, as the speed of new accounts and volume from existing accounts both saw upticks. We estimate the Bulkamid transaction (completed February FY21) to be accretive to ~$0.18 (18% margin) in EPS during the quarter. From the increase in revenue volume, gross margin increased by ~10 percentage points YoY to 72.8%. Moving down the P&L, it bought this down to an operating loss of ~$21.4mm, as operating expense came in 60% higher YoY. Net loss narrowed to ~$21mm, with a $12mm expense for foreign currency translation adjustments, bringing the comprehensive loss to $34mm. The strong quarter sees management lift FY22 guidance to 40% in revenue growth, calling for $253mm at the topline (previously $238mm). It anticipates SNM revenue of ~$205mm and Bulkamid to contribute $48mm, a 111% YoY gain. With respect to CMS outpatient facility rates, for 2023, the relevant sacral neuromodulation codes proposed an increase of 5-7%, whereas the Bulkamid code an increase of ~4%. In terms of catalysts to move the needle, we estimate there is substantial premium yet to be priced in by the market with regards to the company's 4th generation neurostimulator. AXNX submitted its PMA supplement to the FDA back in May on this. Key changes to the current model are around recharging, in that, the new model will only need recharging every 6 months for 1 hour, down from once a month. It expects this to be approved by year's end. AXNX valuation and conclusion Shares are currently trading at 14x TTM sales, well ahead of the GICS Health Care sector peer median of 4.45x. In addition, AXNX looks to be richly priced at 7.3x book value, again far in front of the peer's 2.16x multiple. However, the market has AXNX priced at ~13.3x forward sales, which, we believe, suggests the investors are pricing in an above-sector result for the company at the topline for the coming 12 months. We estimate FY23 sales of $317mm for the company, and at 13x this estimate sets a price target of $84, roughly 18% return potential from the current market price.
Seeking Alpha • Aug 03

Axonics prices stock offering of 1.75M shares

Axonics (NASDAQ:AXNX) priced its earlier announced underwritten public offering of 1.75M shares. Underwriters granted 30-day option to purchase up to 262.5K additional shares. Offer is expected to close on Aug.5, 2022. Net proceeds to be used working capital and general corporate purposes, including a potential $35M milestone payment in connection with its earlier announced and completed acquisition of Contura. Shares trading 3.1% down premarket.
Analyseartikel • Aug 02

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • May 30

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

Axonics is a high-growth medical device play with strong revenue growth drivers. The company’s rechargeable SNM system generates the vast majority of its sales. Long-term investors can buy the company’s shares during pullbacks to maximize their gain.
Analyseartikel • Apr 19

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Aufschlüsselung der Einnahmen und Ausgaben

Wie Axonics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:AXNX Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 24432-628247
30 Jun 24409-226542
31 Mar 24387-1625238
31 Dec 23366-623535
30 Sep 23343-1222333
30 Jun 23320-3221333
31 Mar 23296-4620831
31 Dec 22274-6019634
30 Sep 22241-7618136
30 Jun 22217-7716837
31 Mar 22194-8015139
31 Dec 21180-8013637
30 Sep 21162-7612135
30 Jun 21150-6810934
31 Mar 21120-639532
31 Dec 20112-559229
30 Sep 2087-668927
30 Jun 2053-828724
31 Mar 2039-818223
31 Dec 1914-806820
30 Sep 194-675119
30 Jun 193-493418
31 Mar 192-392119
31 Dec 181-321319
30 Sep 180-281018
30 Jun 180-25717
31 Mar 180-20614
31 Dec 170-18612

Qualität der Erträge: AXNX ist derzeit unrentabel.

Wachsende Gewinnspanne: AXNX ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: AXNX ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 28.1% pro Jahr reduziert.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von AXNX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: AXNX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (14.8%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: AXNX hat eine negative Eigenkapitalrendite (-0.85%), da es derzeit unrentabel ist.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2024/11/14 21:32
Aktienkurs zum Tagesende2024/11/14 00:00
Gewinne2024/09/30
Jährliche Einnahmen2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Axonics, Inc. wird von 7 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Travis SteedBarclays
Travis SteedBofA Global Research
Christopher PasqualeGuggenheim Securities, LLC